Traws Pharma (TRAW) Proxy Filing summary

Executive summary

• Special Meeting scheduled for September 16, 2024, to vote on four key proposals, including share issuance, authorized share increase, reverse stock split, and potential adjournment.

• The meeting follows the April 2024 merger with Trawsfynydd Therapeutics, resulting in a new clinical-stage biopharma focus and a name change.

• Financing of $15 million was secured concurrently with the merger to advance four clinical programs in virology and oncology.

• The board unanimously recommends approval of all proposals, citing enhanced financial resources and strategic positioning.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock upon conversion of Series C Preferred Stock, as required by Nasdaq rules.

• Proposal 2: Approve amendment to increase authorized common shares from 125M to 250M to support future growth and equity incentives.

• Proposal 3: Approve a reverse stock split (ratio between 1-for-15 and 1-for-25) to maintain Nasdaq listing and improve stock price.

• Proposal 4: Approve adjournment of the meeting if more time is needed to solicit votes for the above proposals.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Post-merger board consists of seven members: four from the legacy company and three from Trawsfynydd.

• CEO Werner Cautreels appointed as director; recent resignation of Dr. Fruchtman as President and Chief Scientific Officer, Oncology.

• Directors and officers indemnified for six years post-merger; D&O insurance maintained.